Raising The Bar For Anticoagulants? Warfarin Genotype Results Announced
Executive Summary
Results of a prospective observational study conducted by the pharmacy benefit manager Medco and the Mayo Clinic link more precise warfarin dosing through genotyping to a 30 percent reduction in hospitalization rates from any cause within six months of starting the drug
You may also be interested in...
Genetic Testing For Tamoxifen, Warfarin, Plavix Lacks “Clear Value,” Express Scripts Says
Express Scripts’ caution about the cost effectiveness of some genetic testing could hint at how interested it will be in continuing the pharmacogenomic programs sponsored by former rival PBM Medco, which Express acquired in early April.
With Pradaxa On The Rise, Medco Gathers Evidence On Warfarin Diagnostic Testing
Pharmacy benefits management company Medco Health Solutions Inc. says that with the newly approved oral anticoagulant Pradaxa (dabigatran) off to a good commercial start, it plans to monitor outcomes and compare results with generic warfarin that has been optimized according to genetic testing.
With Pradaxa On The Rise, Medco Gathers Evidence On Warfarin Diagnostic Testing
Pharmacy benefits management company Medco Health Solutions Inc. says that with the newly approved oral anticoagulant Pradaxa (dabigatran) off to a good commercial start, it plans to monitor outcomes and compare results with generic warfarin that has been optimized according to genetic testing.